Publications by authors named "Ingrid Joseph"

Claim this Profile
S
SAR-444245, an engineered not-alpha IL-2 leveraging synthetic biology, modulates critical components of the immune system for durable anti-tumoral activity.
Lina Ma, Nicole V Acuff, Jerod L Ptacin, Carolina E Caffaro, Kristine M San Jose, Ingrid B Joseph

J Immunol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Precision Engineered Interleukin-2 for Bolstering CD8+ T- and NK-cell Activity without Eosinophilia and Vascular Leak Syndrome in Nonhuman Primates.
Lina Ma, Nicole V Acuff, Ingrid B Joseph, Jerod L Ptacin, Carolina E Caffaro, Joseph A Leveque

Cancer Res Commun· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A CD25-biased interleukin-2 for autoimmune therapy engineered via a semi-synthetic organism.
Jerod L Ptacin, Lina Ma, Carolina E Caffaro, Nicole V Acuff, Kristine Germar, Ingrid B Joseph

Commun Med (Lond)· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism.
Jerod L Ptacin, Carolina E Caffaro, Lina Ma, Kristine M San Jose Gall, Hans R Aerni, Ingrid B Joseph

Nat Commun· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peginterferon Beta-1a Shows Antitumor Activity as a Single Agent and Enhances Efficacy of Standard of Care Cancer Therapeutics in Human Melanoma, Breast, Renal, and Colon Xenograft Models.
Antonio Boccia, Cyrus Virata, Daniel Lindner, Nicki English, Nuzhat Pathan, Ingrid B Joseph

J Interferon Cytokine Res· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer.
Michael Mattie, Arthur Raitano, Kendall Morrison, Karen Morrison, Zili An, Ingrid B J Joseph

Mol Cancer Ther· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Evaluation of an Anti-Nectin-4 ImmunoPET Reagent in Tumor-Bearing Mice and Biodistribution Studies in Cynomolgus Monkeys.
Dean O Campbell, Akihiro Noda, Alla Verlinsky, Josh Snyder, Yuji Fujita, Ingrid B J K Joseph

Mol Imaging Biol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of ASG-15ME, a Novel Antibody-Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker.
Kendall Morrison, Pia M Challita-Eid, Arthur Raitano, Zili An, Peng Yang, Joseph D Abad, Ingrid B J Joseph

Mol Cancer Ther· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
Pia M Challita-Eid, Daulet Satpayev, Peng Yang, Zili An, Karen Morrison, Ingrid B J Joseph

Cancer Res· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma.
Fernando Doñate, Arthur Raitano, Kendall Morrison, Zili An, Linnette Capo, Ingrid B J Joseph

Clin Cancer Res· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.
Daniel S Pereira, Claudia I Guevara, Liqing Jin, Nathan Mbong, Alla Verlinsky, Joseph D Abad, Ingrid B J Joseph

Mol Cancer Ther· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
Dowdy Jackson, John Atkinson, Claudia I Guevara, Chunying Zhang, Vladimir Kery, Ingrid Joseph

PLoS One· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics.
Mike Mattie, Ashley Christensen, Mi Sook Chang, William Yeh, Suzanne Said, Ingrid Joseph

Neoplasia· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models.
Jennifer S Michaelson, Rebecca Kelly, Lu Yang, Xiamei Zhang, Kathleen Wortham, Ingrid B J K Joseph

Cancer Biol Ther· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of an Fn14 agonistic antibody as an anti-tumor agent.
Jennifer S Michaelson, Aldo Amatucci, Rebecca Kelly, Lihe Su, Ellen Garber, Ingrid B J K Joseph

MAbs· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.
Jianying Dong, Arlene Sereno, Dikran Aivazian, Emma Langley, Brian R Miller, Ingrid B J K Joseph

MAbs· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery.
Daniel A Erlanson, Joseph W Arndt, Mark T Cancilla, Kathy Cao, Robert A Elling, Ingrid Joseph

Bioorg Med Chem Lett· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity.
Jianying Dong, Arlene Sereno, William B Snyder, Brian R Miller, Susan Tamraz, Ingrid Joseph

J Biol Chem· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response.
Jianying Dong, Stephen J Demarest, Arlene Sereno, Susan Tamraz, Emma Langley, Ingrid Joseph

Mol Cancer Ther· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.
Jennifer S Michaelson, Stephen J Demarest, Brian Miller, Aldo Amatucci, William B Snyder, Ingrid Joseph

MAbs· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
Timothy J Jorgensen, Hui Tian, Ingrid B J K Joseph, Krishna Menon, David Frost

Cancer Chemother Pharmacol· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies.
Wen-Zhen Gu, Ingrid Joseph, Yi-Chun Wang, David Frost, Gerard M Sullivan

Anticancer Drugs· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Debra Ferguson, Luis E Rodriguez, Joann P Palma, Marion Refici, Kenneth Jarvis, Ingrid B J K Joseph

Clin Cancer Res· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of 2-[2-[2-(5-bromo-2- methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model.
Tricia J Vos, Andrei Caracoti, Jennifer L Che, Mingshi Dai, Cheryl A Farrer, Ingrid B J K Joseph

J Med Chem· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis